October 10, 2008 - Brennen Medical said its XenMatriX product for soft tissue reconstruction is now available.
Brennen Medical received clearance to market XenMatriX, via the FDA 510k process, into the surgical hernia market. Surgeons are successfully implanting XenMatriX in ventral hernia/abdominal wall procedures, including complex repairs, according to the company.
XenMatriX is designed for use in the treatment of abdominal wall (hernia) repair where the connective tissue has ruptured. With the aging population and the obesity epidemic, over 30 percent of people over the age of 55 will seek treatment for soft tissue reinforcement. XenMatriX offers a successful alternative to synthetic materials for this population in need of surgical intervention, said the company.
XenMatriX employs a patented technology that maintains an acellular, structurally intact, non-crosslinked porcine dermal matrix for enhanced biocompatibility in host tissue. This non-crosslinked dermal matrix supports tissue revascularization, remodeling and regeneration for abdominal wall and hernia repairs. The compatibility and strength of this material minimizes hernia recurrence and pain, which also reportedly minimizes expense for both the patient and the healthcare environment.
For more information: www.brennenmed.com